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Human West Nile
Virus Infection,
Catalonia, Spain
To the Editor: West Nile virus
(WNV) is a mosquitoborne flavivirus
that is widespread in Africa, the
Middle East, Asia, and southern
Europe, where it causes outbreaks and
sporadic cases of the disease. It has
become an emergent disease in North
America, where it was detected for
the first time in 1999 and became epi-
demic shortly thereafter (1). Although
WNV was initially considered to have
a minor health effect in the
Mediterranean basin, human and
equine outbreaks reported in the last
decade in different countries (2–5)
have made WNV infections a public
health concern.
The epidemiology of WNV in
Europe differs from that in America
and has only been associated with
nonrecurrent, sporadic outbreaks. The
reasons for this difference are contro-
versial; it may be due to environmen-
tal factors, reservoirs, or even mos-
quito vectors. In Spain, neither equine
nor human WNV cases have been
reported. However, some human sero-
surveys that used hemagglutination
inhibition suggested that WNV or
closely related flaviviruses circulated
during the 1970s in the Ebro delta and
areas in Spain (6,7). The Ebro delta, a
wetland in Catalonia, in the northeast
of Spain, is a stopping-off point for
birds migrating between regions of
Africa and Europe where different
WNV vectors and reservoirs have
been identified. The delta could be
considered a high-risk area for WNV
and other arthropodborne virus infec-
tions.
To evaluate WNV seroprevalence
in the human population of the Ebro
delta, a survey was conducted in
2001. After obtaining informed con-
sent, 992 serum samples were
obtained from inhabitants of the area.
The population studied was represen-
tative of the whole area and was strat-
ified by sex and age.
Anti-WNV immunoglobulin G
(IgG) antibodies were determined by
using an in-house indirect enzyme-
linked immunosorbent assay
(ELISA), as previously described (8).
Results were classified as the sample
absorbance/positive control absor-
bance ratio. Samples showing ratio
values >0.2 were tested for WNV IgG
and IgM by using an indirect and a
µ-chain capture ELISA, respectively
(Focus Technologies, Cypress, CA,
USA), and an in-house microneutral-
ization test.
For the microneutralization test,
samples were tested in duplicate and
assayed twice. Twofold dilutions (25
µL) of the samples (1:16–1:256 dilu-
tions) were assayed by using 100
TCID50 (50% tissue culture infectious
dose) of West Nile Eg-101 reference
strain in 96-well tissue culture plates
with Vero cells and after 7 days of
incubation at 37°C and 5% CO2.
Thirty-eight samples showed IgG
ratios >0.2 by the in-house ELISA. Of
these, 12 showed WNV IgG, and 1
was positive for WNV IgM and IgG,
according to the Focus assays. Two
samples showed positive neutralizing
activity, with titers of 32 and 256. The
highest titer was shown by the sample
that yielded positive levels of both
IgM and IgG in the ELISA, which
suggests recent WNV infection.
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Anti-WNV IgG was more often
detected in participants in the 20- to
29-year age group (odds ratio [OR]
4.23, 95% confidence interval [CI]
1.04–16.02, p = 0.03) and in persons
who reported frequent mosquito bites
(OR 8.62, 95% CI 0.44–169, p =
0.08). IgG-positive persons were
equally divided by sex. No significant
differences were found between anti-
body-positive or antibody-negative
persons with respect to their profes-
sion, place of occupation, current res-
idence, time in current residence, out-
door activities, use of insecticides and
repellents, or symptoms related to
WNV infection.
No symptoms related to WNV
infection were reported by the
IgM/IgG-positive participant, who
was 31 years of age, was born in the
area, worked outdoors, and was fre-
quently bitten by mosquitoes. He also
reported travel to Cuba 1 year earlier,
but he had not been vaccinated against
flavivirus, and serologic test results
for dengue were negative.
The other IgG- and neutralizing
antibody–positive participant was 45
years of age and was born and works
in the area. He had never traveled
abroad or been vaccinated against fla-
vivirus. He reported a 4-day fever of
unknown origin during the summer 1
or 2 years before the study. He often
fishes in the areas and is frequently
bitten by mosquitoes.
In conclusion, the study found evi-
dence of recent WNV infections in
humans living in the Ebro delta,
where previous flavivirus circulation
has been suggested by Lozano and
Filipe (6). IgG-positive results not
confirmed by neutralization could be
due to cross-reactive antibodies
induced by other flavivirus infections
or vaccinations (9,10). The probable
WNV infection described was asymp-
tomatic, as occurs in ≈20% of cases.
Other WNV infections in the area
may have remained undetected,
including neuroinvasive cases.
Intensified research and surveillance
in this area will help determine and
refine thresholds for public health
interventions.
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Shigellosis and
Cryptosporidiosis,
Baltimore,
Maryland
To the Editor: Floret et al. argue
convincingly that natural disasters,
including severe floods and wind-
storms, tend not to result in epidemics
of infectious disease (1). This conclu-
sion is consistent with the lack of epi-
demics of shigellosis and cryp-
tosporidiosis after hurricane rains in
Baltimore, Maryland.
Shigellosis and cryptosporidiosis
are associated with waterborne and
foodborne transmission (2,3). We
examined Baltimore shigellosis and
cryptosporidiosis incidence to assess
whether disease risk was related to
temperature or rainfall from January
1, 1998, to December 31, 2004.
Maryland FoodNet supplied case
data; population estimates were
acquired from the Maryland
Department of Planning State Data
Center; and meteorologic data for
Baltimore Washington International
airport (≈10 miles from the city cen-
ter) were obtained from the National
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